Nirvana Life Sciences Valuation

Is NIRV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NIRV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NIRV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NIRV's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NIRV?

Key metric: As NIRV is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NIRV. This is calculated by dividing NIRV's market cap by their current book value.
What is NIRV's PB Ratio?
PB Ratio	-4.5x
Book	-CA$812.35k
Market Cap	CA$3.62m

NIRV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-3.9x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does NIRV's PB Ratio compare to its peers?

The above table shows the PB ratio for NIRV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.5x
HEMP Hempalta	0.7x	n/a	CA$4.3m
XTRX Adastra Holdings	0.2x	n/a	CA$2.5m
THC THC Biomed Intl	0.7x	n/a	CA$3.3m
RVV Revive Therapeutics	0.6x	n/a	CA$4.2m
NIRV Nirvana Life Sciences	n/a	n/a	CA$3.6m

Price-To-Book vs Peers: NIRV has negative equity and a Price-To-Book Ratio (-4.5x) compared to the peer average (0.5x).

Price to Book Ratio vs Industry

How does NIRV's PB Ratio compare vs other companies in the CA Pharmaceuticals Industry?

9 Companies	Price / Book	Estimated Growth	Market Cap
BZAM BZAM	0.08x	n/a	US$4.88m
AVNT Avant Brands	0.1x	n/a	US$4.24m
CPTR Captor Capital	0.07x	n/a	US$1.98m
RAMM RAMM Pharma	0.09x	n/a	US$1.70m

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: NIRV has negative equity and a Price-To-Book Ratio (-4.5x) compared to the Canadian Pharmaceuticals industry average (1.1x).

Price to Book Ratio vs Fair Ratio

What is NIRV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NIRV PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-4.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NIRV's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Cresco Labs

CA$744.9m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CA$1.72

3.0%

-25.2%

Decibel Cannabis

CA$27.7m

An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.

CA$0.065

-50.0%

Bausch Health Companies

US$2.9b

Operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.

BHC

US$11.39

-0.8%

18.8%